Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 study of BRTX-100 in Chronic Lumbar Disc Disease

Next Previous
Trial Profile

A phase 3 study of BRTX-100 in Chronic Lumbar Disc Disease

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 19 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BRTX 100 (Primary)
  • Indications Back pain; Intervertebral disc degeneration
  • Focus Therapeutic Use

Most Recent Events

  • 11 Feb 2026 According to a BioRestorative Therapies media release, based on the positive final official summary of Type B meeting, BioRestorative has initiated Phase 3 enabling activities, with the goal of submitting the Phase 3 IND application in second half of 2026.
  • 05 Dec 2025 New trial record
  • 17 Nov 2025 According to a BioRestorative Therapies media release, the company has been granted type B meeting, in which company intends to request an accelerated timeline for entering a Phase 3 trial to support our BLA application.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top